Document Detail

Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis.
MedLine Citation:
PMID:  19086846     Owner:  NLM     Status:  MEDLINE    
Interstitial fluid pressure is elevated in virtually all solid malignant tumors as a result of abnormalities of the vasculature and interstitium. High interstitial fluid pressure is an independent predictor of disease recurrence in cervical cancer patients treated with radiotherapy, has been implicated as an important factor that impairs the delivery of chemotherapy to tumors and may influence the regulation and distribution of cytokines and growth factors. Targeted molecular treatments that inhibit angiogenesis or alter interstitial fluid dynamics also produce early reductions in interstitial fluid pressure. Reductions in interstitial fluid pressure due to anti-angiogenic treatment have been associated with improved therapeutic outcome in preclinical studies when these agents are combined with radiotherapy or conventional cytotoxic chemotherapy. Pretreatment interstitial fluid pressure and the change in pressure during treatment may provide important predictive information that in the future will be used to optimize therapy in individual patients.
Sarah Jane Lunt; Anthony Fyles; Richard P Hill; Michael Milosevic
Related Documents :
3740566 - Measurement of interstitial fluid pressure: comparison of methods.
7435296 - Colloid osmotic and hydrostatic pressures in chronic subdural haematomas.
19534146 - Two-step optimization of pressure and recovery of reverse osmosis desalination process.
19086846 - Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis.
15466646 - Epicardial stenosis severity does not affect minimal microcirculatory resistance.
1060356 - The shape of the amniotic pressure curve before and after paracervical block during lab...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Future oncology (London, England)     Volume:  4     ISSN:  1744-8301     ISO Abbreviation:  -     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-17     Completed Date:  2009-03-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101256629     Medline TA:  Future Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  793-802     Citation Subset:  IM    
Division of Applied Molecular Oncology, Princess Margaret Hospital/Ontario Cancer Institute, University Health Network, Department of Medical Biophysics, University of Toronto, Toronto, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Extracellular Fluid*
Neoplasms / blood supply,  pathology*
Neovascularization, Pathologic / pathology*
Tumor Markers, Biological / analysis*
Reg. No./Substance:
0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Surgical oophorectomy for breast cancer: back to the future.
Next Document:  Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets.